Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 68788-4060

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 68788-4060). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rabeprazole Sodium Delayed-release Tablets 20mg (20mg Container 30tablets)

Label for Rabeprazole Sodium Delayed-Release Tablets 20 mg, generic for Aciphex, manufactured by Torrent Pharma Inc., Basking Ridge, NJ. The label includes dosage form and strength, storage instructions, and warnings. It features directions in English and Spanish, barcodes, and space for lot, batch, and expiration information. The background includes yellow highlights around the product name and Spanish instructions.*

FDA Label Image

Structure (4d1e141f 24d6 41e0 A671 48ff69147297 01)

Chemical structure of rabeprazole sodium showing its molecular arrangement with sodium, sulfur, nitrogen, oxygen, and carbon atoms connected in a specific structural layout.*

FDA Label Image

Figure 2 (4d1e141f 24d6 41e0 A671 48ff69147297 02)

A line graph showing mean daytime heartburn scores over a period of days for three groups: placebo, rabeprazole 10 mg, and rabeprazole 20 mg. The y-axis represents mean heartburn scores from 0 (none) to 4 (very severe), and the x-axis shows study days from -14 to 28. The graph tracks changes in heartburn severity before and after treatment start (day 0) for each group.*

FDA Label Image

Figure 3 (4d1e141f 24d6 41e0 A671 48ff69147297 03)

A line graph titled 'Mean Nighttime Heartburn Scores RAB-USA-2' showing mean heartburn scores over a 28-day study period. The x-axis represents study days from -14 to 28, and the y-axis shows the mean score from 0 to 4. Three lines compare placebo, Rabeprazole sodium 10 mg, and Rabeprazole sodium 20 mg groups, illustrating changes in heartburn severity scores over time.*

FDA Label Image

Figure 4 (4d1e141f 24d6 41e0 A671 48ff69147297 04)

A line chart titled 'Mean Daytime Heartburn Scores RAB-USA-3' comparing heartburn scores over time between a placebo group (n=58) and a Rabeprazole sodium 20 mg group (n=59). The x-axis represents study days from -14 to 28, and the y-axis is the mean heartburn score ranging from 0 (none) to 4 (very severe). The graph shows declining heartburn severity scores for the Rabeprazole group compared to the placebo after day 0.*

FDA Label Image

Figure 5 (4d1e141f 24d6 41e0 A671 48ff69147297 05)

A line graph titled 'Mean Nighttime Heartburn Scores RAB-USA-3' comparing mean heartburn scores over 28 study days between two groups: a placebo group (n=58) and a Rabeprazole 20 mg group (n=59). The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores ranging from 0 to 4. Scores are defined from 0 (none) to 4 (very severe).*

FDA Label Image

Logo (4d1e141f 24d6 41e0 A671 48ff69147297 06)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.